62 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
New Strong Sell Stocks for April 11th http://www.zacks.com/stock/news/256038/new-strong-sell-stocks-for-april-11th?cid=CS-ZC--256038 Apr 11, 2017 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed http://www.zacks.com/stock/news/252292/sucampo-scmp-beats-q4-earnings-2017-view-reaffirmed?cid=CS-ZC-FT-252292 Mar 09, 2017 - Sucampo Pharmaceuticals, Inc. (SCMP) reported adjusted earnings of 68 cents per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 49 cents by 38.8%.
New Strong Sell Stocks for July 28th http://www.zacks.com/stock/news/225559/new-strong-sell-stocks-for-july-28th?cid=CS-ZC-FT-225559 Jul 28, 2016 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
Dr. Reddy's (RDY) Q1 Earnings and Revenues Decline Y/Y http://www.zacks.com/stock/news/225226/dr-reddys-rdy-q1-earnings-and-revenues-decline-y-y?cid=CS-ZC-FT-225226 Jul 27, 2016 - Dr. Reddy's (RDY) reported first-quarter fiscal 2017 earnings per American Depositary Share of 11 cents, down 79.6% from the year-ago quarter.
Dr. Reddy's Laboratories' (RDY) Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3991851-dr-reddys-laboratories-rdy-q2-2016-results-earnings-call-transcript?source=feed_tag_india Jul 27, 2016 - Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2016 Earnings Conference Call July 26, 2016 09:00 ET Executives Kedar Upadhye - Investor Relations Saumen Chakraborty - Chief Financial Officer Abhijit M
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain http://www.zacks.com/stock/news/223394/teva-teva-provides-2016-2019-outlook-shares-gain?cid=CS-ZC-FT-223394 Jul 14, 2016 - Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
Looking For Generic Drug Stocks? Pick Up These Winners http://www.zacks.com/stock/news/223371/looking-for-generic-drug-stocks-pick-up-these-winners?cid=CS-ZC-FT-223371 Jul 13, 2016 - The short term earnings outlook for these stocks have been building momentum recently, so don't miss out!
Dr. Reddy's Laboratories' (RDY) Management Discusses on Q3 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3879876-dr-reddys-laboratories-rdy-management-discusses-q3-2016-results-earnings-call-transcript?source=feed_tag_india Feb 09, 2016 - Dr. Reddy's Laboratories Limited (NYSE:RDY) Q3 2016 Earnings Conference Call February 9, 2016 8:00 AM ET Executives Kedar Upadhye – Investor Relations Saumen Chakraborty – Chief Financial Officer Abhi
Dr. Reddy's Laboratories' (RDY) CFO Saumen Chakraborty on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3620746-dr-reddys-laboratories-rdy-cfo-saumen-chakraborty-on-q2-2016-results-earnings-call-transcript?source=feed_tag_india Oct 29, 2015 - Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2016 Earnings Conference Call October 29, 2015, 09:00 AM EDT Executives Kedar Upadhye - Head of Global Generics Finance & Investor Relations Saumen C
BioMarin-Dr. Reddy's Agree to Settle Kuvan Patent Litigation http://www.zacks.com/stock/news/190775/biomarin-dr-reddys-agree-to-settle-kuvan-patent-litigation?cid=CS-ZC-FT-190775 Sep 21, 2015 - BioMarin (BMRN) announced that it has entered into a settlement agreement with Dr. Reddy's (RDY) to resolve the patent litigation related to Kuvan.

Pages: 1234567

<<<Page 5>